FDA Approvals, News & UpdatesMultiple Myeloma

FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma

Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.
April 2021 Vol 7 No 2

In March 2021, the FDA approved Abecma (idecabtagene vicleucel; from Bristol Myers Squibb/Bluebird Bio), a BCMA-directed, genetically modified CAR T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or returned, after 4 or more lines of therapy. Abecma is the first gene therapy approved by the FDA for the treatment of multiple myeloma.

“While there is no cure for multiple myeloma, the long-term outlook can vary based on the individual’s age and the stage of the condition at the time of diagnosis. Today’s approval provides a new treatment option for patients who have this uncommon type of cancer,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.

According to the National Cancer Institute, in 2020 multiple myeloma accounted for approximately 32,000 of all new cancer cases in the United States.

The FDA approved Abecma based on a study of 127 patients with relapsed or refractory multiple myeloma who had received 3 or more lines of therapy. Approximately 88% of the patients had received 4 or more lines of therapy.

Overall, 72% of patients had a response to Abecma, and 28% of them had a complete response (or remission), most (65%) of which lasted 12 months or more.

The most common side effects of Abecma include cytokine release syndrome, infections, fatigue, musculoskeletal pain, and a weakened immune system. Side effects usually appear within the first 1 or 2 weeks after treatment, but some may occur later.

Share this:

Recommended For You
Patient StoriesMultiple Myeloma
Living My Life While Dealing with Multiple Myeloma
By Thomas Goode
Thomas Goode always worked out; when he felt an excruciating pain on his left side one day working out, he knew something was wrong and visited a surgeon. After terrible back pain months later and another x-ray and MRI, he was diagnosed with multiple myeloma.
Letters to the EditorMultiple Myeloma
Thank You CONQUER Magazine for a Great Article
By Sally K. Koski, PhD, RN
Sally K. Koski, PhD, RN, expresses her gratitude to CONQUER magazine for the very informative article, “Multiple Myeloma: Navigating the First 90 Days,” which was featured in the April 2022 issue.
Multiple MyelomaPatient Stories
Targeting a Better Future for Patients with Multiple Myeloma
By Christopher Greklek
Christopher Greklek competed in Ironman races and was shocked when he was diagnosed with multiple myeloma. He describes being in and out of remission repeatedly, citing a program seeking to improve patient options.
Last modified: March 10, 2022

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest